Current and future developments in the use of temozolomide for the treatment of brain tumours (Q34571908)

3 August 2017

1 reference

title

Current and future developments in the use of temozolomide for the treatment of brain tumours (English)

1 reference

3 August 2017

0 references

R Stupp

1

1 reference

3 August 2017

M Gander

series ordinal

2

1 reference

3 August 2017

S Leyvraz

series ordinal

3

1 reference

3 August 2017

E Newlands

series ordinal

4

1 reference

3 August 2017

publication date

1 September 2001

1 reference

Lancet Oncology Commission

3 August 2017

published in

1 reference

3 August 2017

volume

2

1 reference

3 August 2017

issue

9

1 reference

3 August 2017

page(s)

552-560

1 reference

From triazines and triazenes to temozolomide.

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

Intracellular Localization and intercellular heterogeneity of the human DNA repair protein O(6)-methylguanine-DNA methyltransferase

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one , a novel broad-spectrum antitumor agent

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

Antitumor imidazotetrazines. 32. Synthesis of novel imidazotetrazinones and related bicyclic heterocycles to probe the mode of action of the antitumor drug temozolomide.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

O6-alkylguanine-DNA alkyltransferase activity in human brain and brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

Survival of human glioma cells treated with various combination of temozolomide and X-rays

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

Irinotecan therapy in adults with recurrent or progressive malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

New antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

Looking through the retrospectoscope in the era of evidence-based medicine.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

Understanding low-grade glioma: a decade of progress

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

Long-term outcome of low-grade oligodendroglioma and mixed glioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

Acute leukemia following treatment of malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

Long-term complications of cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900489-2

7 January 2021

10.1016/S1470-2045(01)00489-2

Identifiers

DOI

1 reference

3 August 2017

1 reference